Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,847 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pembrolizumab Clear all
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
65
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

NCT03586024
View directory record Official record
Conditions
Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 28, 2026, 1:23 PM EDT
Completed No phase listed Observational

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

NCT03356470
View directory record Official record
Conditions
Melanoma
Interventions
F-FDG PET/CT
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Recruiting Phase 1 Interventional

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03260322
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP8374, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

NCT04869137
View directory record Official record
Conditions
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
Interventions
Lenvatinib Oral Product, Pembrolizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

NCT03505320
View directory record Official record
Conditions
Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
Interventions
zolbetuximab, oxaliplatin, leucovorin, fluorouracil, Pembrolizumab, folinic acid, nivolumab, Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239
View directory record Official record
Conditions
Neoplasms
Interventions
BI 765179, Ezabenlimab, Pembrolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

NCT02446457
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab, Rituximab
Other · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Corona, California • Duarte, California • Lancaster, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

NCT03240211
View directory record Official record
Conditions
PTCL, CTCL
Interventions
Pembrolizumab, Pralatrexate, Decitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Not listed Phase 2 Interventional

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

NCT04622007
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tomivosertib, Pembrolizumab, Pemetrexed
Drug · Biological
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
131
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 1 Interventional

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
Biological · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
66
States / cities
Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT03123055
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
B-701, Pembrolizumab
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

NCT03995147
View directory record Official record
Conditions
B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Interventions
Pembrolizumab, R-CHOP Protocol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT04862455
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab, Stereotactic Body Radiation Therapy
Other · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

NCT03921021
View directory record Official record
Conditions
Esophagogastric Adenocarcinoma
Interventions
Telomelysin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 28, 2026, 1:23 PM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

NCT03006302
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Epacadostat, Pembrolizumab, CRS-207, Cyclophosphamide, GVAX Pancreas Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 28, 2026, 1:23 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124
View directory record Official record
Conditions
Prostate Cancer, High-risk Prostate Cancer
Interventions
Darolutamide, Pembrolizumab, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 1:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 1:23 PM EDT